Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Tongji Xie"'
Autor:
Yan Li, Tongji Xie, Shouzheng Wang, Lin Yang, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Junling Li, Jianming Ying, Puyuan Xing
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Small-cell lung cancer (SCLC) transformation accounts for 3–14% of resistance in EGFR-TKI relapsed lung adenocarcinomas (LUADs), with unknown molecular mechanisms and optimal treatment strategies. We performed transcriptomic analyses (incl
Externí odkaz:
https://doaj.org/article/f112bbf4a98c456d876274631e76d926
Autor:
Ruyun Gao, Ning Lou, Lin Li, Tongji Xie, Puyuan Xing, Le Tang, Jiarui Yao, Xiaohong Han, Yuankai Shi
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Introduction Identifying new biomarkers for predicting immune checkpoint inhibitors (ICIs) response in non-small cell lung cancer (NSCLC) is crucial. We aimed to assess the variant allele frequency (VAF)-related profile as a novel biomarker
Externí odkaz:
https://doaj.org/article/01d8a74ab1f0446cac8f66bf6e86e1fd
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-25 (2024)
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy characterized by varied responses to treatment and prognoses. Understanding the metabolic characteristics driving DLBCL progression is crucial for developing pers
Externí odkaz:
https://doaj.org/article/140674df43274333abe54ca203218d11
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 9, Pp n/a-n/a (2024)
Abstract Intra‐tumour immune infiltration is a crucial determinant affecting immunotherapy response in non‐small cell lung cancer (NSCLC). However, its phenotype and related spatial structure have remained elusive. To overcome these restrictions,
Externí odkaz:
https://doaj.org/article/7f45e31e59ea47cea124100767cd8b7a
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-16 (2024)
Abstract In hepatocellular carcinoma (HCC), classical cancer stem cells (CSC) markers were shared by normal stem cells, targeting which may hinder hepatic regeneration and cause liver failure. Additionally, the spatial structure of CSC still remained
Externí odkaz:
https://doaj.org/article/75f5b29ff4ac4d5993f48a60725f5cd9
Autor:
Yixiang Zhu, Chengcheng Liu, Ziyi Xu, Zihua Zou, Tongji Xie, Puyuan Xing, Le Wang, Junling Li, Xiangxiang Pan, Peifang Wei
Publikováno v:
Chinese Medical Journal, Vol 136, Iss 21, Pp 2551-2561 (2023)
Abstract. Background:. The brain is a common metastatic site in patients with non-small cell lung cancer (NSCLC), resulting in a relatively poor prognosis. Systemic therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs
Externí odkaz:
https://doaj.org/article/4f70020e440d473c955a2cc812ed25d4
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-17 (2023)
Abstract Background Pulmonary large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC) are two types of high-grade neuroendocrine carcinomas of the lung with poor prognosis. LCNEC has not been thoroughly studied due to its rarity
Externí odkaz:
https://doaj.org/article/6d9b29c0eea64f50a4b18f973f7a35ae
Autor:
Dantong Sun, Feiyue Feng, Fei Teng, Tongji Xie, Jinsong Wang, Puyuan Xing, Haili Qian, Junling Li
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Introduction Dysregulated ARID1A expression is frequently detected in lung adenocarcinoma (LUAD) and mediates significant changes in cancer behaviors and a poor prognosis. ARID1A deficiency in LUAD enhances proliferation and metastasis, whic
Externí odkaz:
https://doaj.org/article/b44b859bf4da482ab95281c171696e57
Publikováno v:
iScience, Vol 26, Iss 10, Pp 107894- (2023)
Summary: Senescent tumor cells (STCs) can induce immunosuppression, promoting tumor progression and therapy resistance. However, the specific characteristics of immunosuppressive STC have not been thoroughly investigated. This study aimed to characte
Externí odkaz:
https://doaj.org/article/a0d8da799a0a4ed4b056159a6eddc59d
Publikováno v:
Cell Communication and Signaling, Vol 20, Iss 1, Pp 1-16 (2022)
Abstract Introduction EGFR mutations in non-small cell lung cancer (NSCLC) are associated with a poor response to immune checkpoint inhibitors (ICIs), and only 20% of NSCLC patients harboring EGFR mutations benefit from immunotherapy. Novel biomarker
Externí odkaz:
https://doaj.org/article/9a8ab563b265415784c3f95e460f70bd